| scholarly article | Q13442814 |
| P2093 | author name string | John Hoskins | |
| Emily Y Chew | |||
| Michael J Elman | |||
| Amitha Domalpally | |||
| Ronald P Danis | |||
| Gary Gensler | |||
| Traci E Clemons | |||
| Barbara Blodi | |||
| Michael Rauser | |||
| G Baker Hubbard | |||
| Gary E Fish | |||
| Jack Wells | |||
| Alan Margherio | |||
| Alexander Brucker | |||
| P2860 | cites work | Complement factor H polymorphism in age-related macular degeneration | Q24553334 |
| mTOR signaling in growth control and disease | Q24634174 | ||
| An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration | Q28190470 | ||
| Complement factor H variant increases the risk of age-related macular degeneration | Q28239239 | ||
| Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration | Q28290149 | ||
| Complement factor H polymorphism and age-related macular degeneration | Q29614931 | ||
| Prevalence of age-related macular degeneration in the United States | Q29614964 | ||
| Immunological and aetiological aspects of macular degeneration | Q34207836 | ||
| mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. | Q34429001 | ||
| Age-related macular degeneration: genetics and biology coming together | Q34440797 | ||
| Complement activation and inflammatory processes in Drusen formation and age related macular degeneration | Q34521109 | ||
| A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis | Q34709640 | ||
| A role for local inflammation in the formation of drusen in the aging eye. | Q34809064 | ||
| Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial | Q34956193 | ||
| The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation | Q35125756 | ||
| Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment | Q35675501 | ||
| Sirolimus-eluting coronary stent. | Q35689893 | ||
| Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT) | Q35742777 | ||
| The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates | Q36217662 | ||
| A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants | Q36556369 | ||
| Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study | Q36722548 | ||
| Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial | Q36801990 | ||
| Retinal precursors and the development of geographic atrophy in age-related macular degeneration. | Q36991543 | ||
| Immunology of age-related macular degeneration | Q37614752 | ||
| Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept | Q38761162 | ||
| NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication | Q40781341 | ||
| Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration | Q42463987 | ||
| Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration | Q44360148 | ||
| Tolerability and pharmacokinetics of intravitreal sirolimus | Q46068830 | ||
| Causes and prevalence of visual impairment among adults in the United States | Q46890945 | ||
| Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression | Q57362835 | ||
| A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema | Q82671785 | ||
| P433 | issue | 5 | |
| P921 | main subject | sirolimus | Q32089 |
| eye disease | Q3041498 | ||
| geographic atrophy | Q47200750 | ||
| P304 | page(s) | 441-450 | |
| P577 | publication date | 2018-05-01 | |
| P1433 | published in | Ophthalmology Retina | Q63241478 |
| P1476 | title | Treatment of Geographic Atrophy with Intravitreal Sirolimus: The Age-Related Eye Disease Study 2 Ancillary Study | |
| P478 | volume | 2 |
Search more.